



Consultations

Consultation on the draft 2025/26 Invitation to Tender (for healthcare professionals)

30 July 2025

Overview

Pharmac | Te Pātaka Whaioranga is seeking feedback from healthcare professionals, medical groups, hospital pharmacies, and other interested parties on the draft 2025/26 Invitation to Tender.

Consultation closes at 4 pm (New Zealand standard time) on Monday 10 September 2025.

Submit feedback through our [online form](#) or email tenderconsult@pharmac.govt.nz

We are seeking feedback on the draft 2025/26 Invitation to Tender. The list of medicines proposed for inclusion in the 2025/26 Invitation to Tender is still under development and may change before the final 2025/26 ITT is issued. In particular, we are seeking:

We're particularly interested in feedback on the following questions:

- whether a brand change for any of the medicines included in the draft tender list would not be appropriate, and why?
- whether Pharmac should delay or avoid a brand change for any of these medicines and, if so, why?
- are there any features of the medicines that we should consider when evaluating them?
- what are the potential benefits, issues, or consequences of dispensing 3 months supply of any of these medicines at once?
- are there potential benefits, issues, or consequences if we removed any funding restrictions from the medicine (such as Special Authority criteria)?
- which medicines, indications (uses), or population groups might need an alternative brand if a brand change were to occur and why?
- are the proposed Additional Special Terms for intra-uterine devices [non-hormonal] (IUDs) appropriate?
- For intra-uterine devices [non-hormonal] (IUDs), we are considering making a MDR certification a mandatory requirement, rather than a preference. What are the

potential issues, benefits or consequences of this change?

We welcome any other feedback you may wish to provide. Please contact us if you wish to discuss anything in this consultation.

We are also seeking feedback from the industry and people who take medicines.

- [Industry consultation](#)
- [Consumer consultation](#)

Please share this consultation with others who you think might be interested. We want to hear feedback from a range of people.

About the tender

Pharmac's annual tender is used to contract for supply of medicines. Most of these medicines are already funded in New Zealand and are no longer under patent.

The tender helps to secure the ongoing supply of medicines and generate savings. These savings can be used to fund new medicines. Each year, some of the medicines on the Pharmaceutical Schedule (the list of funded medicines) are included in the annual tender. Although the tender is run annually, the list of medicines included in it changes from year to year. Typically, each medicine is tendered every three years.

Before we run the tender each year, we seek feedback from healthcare professionals, consumer groups, the pharmaceutical industry and the public. This can tell us if:

- tendering is appropriate for each medicine
- there are any potential issues when considering a change in brand for a particular medicine

We get expert advice from Pharmac's [Tender Clinical Advisory Committee](#) on every tender decision we make. The committee is made up of healthcare professionals, including doctors, nurse practitioners, and pharmacists. We'll also seek additional advice from specialists in particular fields, such as cancer or mental health, as needed.

The feedback and advice we get makes sure our decision supports New Zealanders to live longer, healthier lives.

New round of consultation

For last year's invitation to tender, Pharmac introduced an extra consultation step. This was intended to help us better understand what a brand change could mean to people and how we could best support any change.

We did two consultations:

- [28 May 2025 | Consultation on possible brand changes through the annual tender](#)
- [8 July 2025 | Second consultation on possible brand changes through the annual tender July 2025](#)

This additional consultation step will be incorporated into the 2025/26 annual Invitation to Tender and for future tenders.

What the tender means

If we award a tender for a medicine to a pharmaceutical supplier, then that supplier's brand becomes the principal funded brand of that medicine. It would likely be the only brand of that

medicine funded on the Pharmaceutical Schedule (Principal Supply Status). For this tender round, Principal Supply Status would be in place until 30 June 2029. Principal Supply Status means that if a supplier is selected, they become the main supplier of that medicine in New Zealand with a guaranteed supply of at least 95% of the total funded market.

There may be no change

If the brand awarded the tender was already the only funded brand, there would be no noticeable difference for most people, although the price that Pharmac pays may change.

Many funded brands may change to only one funded brand

If that brand was one of multiple funded brands, we would transition from the various funded brands to the brand that has been awarded the tender (and therefore would have Principal Supply Status). The other brands would be removed from the Pharmaceutical Schedule. Usually, this transition lasts for five months.

A new funded brand may replace an existing one

If that brand was not already funded, we would transition from the old brand to the new one over time. The new brand is listed on the Pharmaceutical Schedule, and there is then a period of time when both the old and new brands would be available and funded. The old brand is then removed from the Pharmaceutical Schedule. Usually, this transition lasts for five months. We notify of any upcoming changes at least one month before any changes occur.

Access to other brands if a tender is awarded to a new brand

Most people will start on, or move to, the new brand easily. However, we understand that people's experiences when taking medicines may be different. We use an "alternative brand allowance" (ABA) to support people who may experience, or are at heightened risk of, adverse outcomes from a brand change. This may mean:

- moving back to the old brand after adverse side effects
- having a longer period to change brands
- allowing some people to avoid switching altogether.

The structure of the tender gives Pharmac the flexibility to fund alternative brands in different ways. For example:

- in hospitals, we would use the alternative brand allowance provisions in the Schedule. This lets hospitals purchase alternative brands up to a certain percent of volume, typically 5 percent.
- in the community, alternative brands could be funded through listing (or maintaining the listing of) other brands under Special Authority criteria, or
- managing case-by case approvals through our Exceptional Circumstances framework.

While Pharmac can fund alternative brands, continued supply of a particular alternative brand cannot always be guaranteed. It is helpful to understand what medicines might need access to alternative brands before we run the tender.

We are keen to understand:

- which medicines, indications, or population groups might need funding for an alternative brand, and if so, why?

- are there any particular features of the medicines that we should be considering when evaluating potential medicines?

Other potential changes

The tender can result in substantial price reductions, and we can use the savings to fund new medicines. We also use the savings to fund changes to the tendered medicines. For example:

- We might change or remove funding restrictions so more people can use it (for example, a Special Authority restriction, endorsement, or prescriber-type restriction). We might consult on this separately before making a decision.
- If the medicine is currently partially funded, it could become fully funded if the tender were awarded.
- We might change the amount of medicine that could be dispensed at a time – for example we might let people collect three months' supply of medicine at a time instead of one month.
- Some medicines or formulations may become funded for the first time through the tender.

We are interested in your feedback on potential changes for the medicines we are tendering. You can see the Pharmaceutical Schedule for all dispensing and funding restrictions:

<https://pharmac.govt.nz/pharmaceutical-schedule>

Additional Special Terms

We have included Additional Special Terms in the draft 2025/26 Invitation to Tender contract for intra-uterine devices [Non-hormonal] (IUDs). This clause would require that potential suppliers offer education, training, and support resources to safely use the supplier's IUD product. This could include a description of the inserter and IUD materials and insertion instructions.

Any feedback on these Additional Special Terms will help inform the final contract.

Intra-uterine device (Non-hormonal)

You shall provide the following information when submitting a Tender Bid for the Pharmaceutical intra-uterine device [Non-hormonal] (IUD Tender Item):

- the size of the IUD Tender Item, including length and width measurements as well as the diameter of the inserter;
- a description of the material the inserter is made of;
- the duration of the therapeutic effect of the IUD Tender Item; and
- the metals which are contained in the IUD Tender Item.

You shall provide the following Resources at no cost for the IUD Tender Item, for the provision of education, training and support to healthcare professionals in respect of the use of the IUD Tender Item.

For the purposes of this clause "Resources" shall include but not be limited to the:

- provision of training materials (DVDs, pamphlets, leaflets, brochures) to healthcare professionals;

- provision of an information sheet explaining the differences between the current brand of intra-uterine device and your IUD Tender Item; and
- provision of presentations and/or demonstrations on the use of your IUD Tender Item to patients and/or healthcare professionals.

The tender list

See **Schedule Two: Products to be tendered (draft, by therapeutic group)** for the list of medicines that we are proposing to include in this year's tender. Medicines have been grouped according to the therapeutic group classification system used in the Pharmaceutical Schedule.

Below is a list of these groups, and the corresponding page numbers. Medicines with multiple indications only appear in one group.

Therapeutic group	Pages
Alimentary Tract and Metabolism	11 - 12
Blood and Blood Forming Organs	12
Cardiovascular System	13- 16
Dermatologicals	16 - 18
Genito-Urinary System	18
Hormone Preparations	18 - 19
Infections	19 - 21
Musculoskeletal System	21
Nervous System	22 - 25
Oncology and Immunosuppressants	25 - 26
Respiratory	26
Sensory Organs	26

This year's draft Invitation to Tender includes 61 tender items that have not previously been included in the tender and/or are not currently listed on the Pharmaceutical Schedule. These tender items are as follows:

Tendered Item
Adapalene (current access) <ul style="list-style-type: none"> • Crm 0.1% • Gel 0.1%
Adapalene (widened access) <ul style="list-style-type: none"> • Crm 0.1% • Gel 0.1%
Amiloride hydrochloride with furosemide <ul style="list-style-type: none"> • Tab 5 mg with furosemide 40 mg
Aripiprazole <ul style="list-style-type: none"> • Tab 5 mg

Benzyl benzoate (funded with restriction) ¹ <ul style="list-style-type: none"> • 10% - 25%
Benzyl benzoate (funded without restriction) ¹ <ul style="list-style-type: none"> • 10% - 25%
Calcium folinate <ul style="list-style-type: none"> • Inj 350 mg
Colistin sulphomethate <ul style="list-style-type: none"> • Inj 1,000,000 - 4,500,000 iu
Cefuroxime Sodium ² <ul style="list-style-type: none"> • Inj 250 mg
Duloxetine ² <ul style="list-style-type: none"> • Cap 30 mg • Cap 60 mg
Furosemide [Frusemide] ² <ul style="list-style-type: none"> • Tab 20 mg
Hydrocortisone with paraffin liquid and lanolin <ul style="list-style-type: none"> • Lotn 1% with paraffin liquid and lanolin (pack size 50 - 250 ml)
Hyoscine hydrobromide <ul style="list-style-type: none"> • Patch 1 mg per 72 hours
Ibuprofen* <ul style="list-style-type: none"> • Tab 200 mg - blister pack (pack size greater than or equal to 100 and less than or equal to 1,000) • Tab 200 mg - blister pack (pack size less than or equal to 20)¹
Ivabradine <ul style="list-style-type: none"> • Tab 5 mg
Lithium carbonate <ul style="list-style-type: none"> • Immediate-release tab/cap
Malathion (funded with restriction) ¹ <ul style="list-style-type: none"> • 0.5%
Malathion (funded without restriction) ¹ <ul style="list-style-type: none"> • 0.5%
Minocycline hydrochloride ¹ <ul style="list-style-type: none"> • Inj 100 - 200 mg
Morphine <ul style="list-style-type: none"> • Oral liq 1 mg per ml • Oral liq 2 mg per ml • Oral liq 5 mg per ml • Oral liq 10 mg per ml
Omeprazole <ul style="list-style-type: none"> • Inf 40 mg
Pancreatic enzyme ²

<ul style="list-style-type: none"> • Cap 175 mg • Cap 420 mg
<p>Paracetamol*</p> <ul style="list-style-type: none"> • Tab 500 mg - blister pack (pack size greater than or equal to 100 and less than or equal to 1,000) • Tab 500 mg - bottle pack (pack size greater than or equal to 1,000)
<p>Perindopril with amlodipine²</p> <ul style="list-style-type: none"> • Tab 10 mg with amlodipine 10 mg • Tab 10 mg with amlodipine 5 mg • Tab 5 mg with amlodipine 10 mg • Tab 5 mg with amlodipine 5 mg
<p>Permethrin (combined market)²</p> <ul style="list-style-type: none"> • Crm 5%
<p>Permethrin (split market)²</p> <ul style="list-style-type: none"> • Crm 5%
<p>Prasugrel²</p> <ul style="list-style-type: none"> • Tab 5 mg • Tab 10mg
<p>Rifampicin with isoniazid and ethambutol and pyrazinamide¹</p> <ul style="list-style-type: none"> • 150 mg with isoniazid 75 mg and ethambutol 275 mg and pyrazinamide 400 mg
<p>Rifampicin with isoniazid and pyrazinamide¹</p> <ul style="list-style-type: none"> • 150 mg with isoniazid 75 mg and pyrazinamide 400 mg
<p>Rosuvastatin (current access)</p> <ul style="list-style-type: none"> • Tab 5 mg • Tab 10 mg • Tab 20 mg • Tab 40 mg
<p>Rosuvastatin (widened access)</p> <ul style="list-style-type: none"> • Tab 5 mg • Tab 10 mg • Tab 20 mg • Tab 40 mg
<p>Sulfadiazine silver</p> <ul style="list-style-type: none"> • 1%
<p>Telmisartan²</p> <ul style="list-style-type: none"> • Tab 40 mg • Tab 80 mg
<p>Telmisartan with amlodipine²</p> <ul style="list-style-type: none"> • Tab 40 mg with amlodipine 10 mg • Tab 40 mg with amlodipine 5 mg • Tab 80 mg with amlodipine 10 mg

<ul style="list-style-type: none"> • Tab 80 mg with amlodipine 5 mg
Vancomycin hydrochloride (current access) ¹ <ul style="list-style-type: none"> • Cap 125 mg • Cap 250 mg
Vancomycin hydrochloride (widened access) ¹ <ul style="list-style-type: none"> • Cap 125 mg • Cap 250 mg
<p>¹These items are not currently listed on the Pharmaceutical Schedule and have never been included in the tender.</p> <p>²These items are not currently listed on the Pharmaceutical Schedule and have been included in the tender.</p> <p>*Please note that Ibuprofen Tab 200 mg and Paracetamol Tab 500 mg have been included in previous tenders, however, the specific pack sizes being tendered this year have not been tendered before.</p>

Information provided for each medicine

For each medicine (as defined by chemical name, form, and strength), we have provided where applicable:

- the current subsidy paid per unit (e.g. capsule, tablet, injection) as of 1 July 2025. These values are ex-manufacturer excluding GST
- the number of units funded in the community per year in the year ending 30 June 2025 These may be partially funded or full funded
- an estimate of the annual community-market value based on the current subsidy paid per unit. This is estimated by multiplying the volume of units used in the year ending 30 June 2025 by the current listed unit subsidy as of 1 July 2025
- comments specifically relating to the tender item and/or its current listing on the Pharmaceutical Schedule
- please note that these volumes and figures are approximate and indicative only. Pharmac makes no representation as to the accuracy of these volumes and figures or the level of sales or likely sales of any tender item

Explanation of terms, symbols, and abbreviations

“Tab” means tablet, “cap” means capsule, “liq” means liquid, “inj” means injection, “suppos” means suppository, “grans” mean granules and “OP” means original pack to be dispensed.

Symbols used in the draft tender list:

Symbol	Explanation
Underlined	Tender items where there is currently a principal supply contract are underlined. The price and subsidy for these items are fixed until 30 June 2025 unless otherwise stated in the comments column, therefore a listing of a new brand could only occur after that date.
C	To be tendered for Principal Supply Status (community medicines).
H	To be tendered for Principal Supply Status (hospital medicines).
PCT	Pharmaceuticals Health New Zealand Te Whatu Ora hospitals may claim a subsidy through Section B of the Pharmaceutical Schedule.
+	Pharmac has been advised of the existence of a patent.
*	There is no fully funded medicine available for this tender item (in relation to community supply).
@	Additional Stock Pharmaceuticals (ASP). The supplier of the successful tender bid would be required to hold additional stock.
#	A rebate currently exists.

Key dates

30 July 2025 – Consultation begins

10 September 2025 – Consultation closes

September 2025 – Tender Clinical Advisory Committee meets

Late October/Early November 2025 – Final Invitation to Tender issued

December 2025 – Invitation to Tender closes

January 2026 – Earliest tender results announced

April 2026 – Earliest listing of new brands

Providing feedback

Feedback should be provided to the tender analysts via our [online form](#) or by emailing tenderconsult@pharmac.govt.nz

All feedback received before the closing date will be considered by Pharmac’s Board or its delegate before finalising the 2025/26 Invitation to Tender.

Your feedback may be shared

When you give feedback on a consultation, your feedback becomes official information that Pharmac holds. Pharmac has legal responsibilities for how we

manage this official information, under laws such as the Official Information Act and Privacy Act.

Pharmac may receive a request from people for official information, which could include your feedback. Legally, Pharmac must consider whether your feedback should be released. Tell us if there is anything about your feedback that you would prefer wasn't released and we will take that into consideration.

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Alimentary Tract and Metabolism

Chemical Name	Units	Cost	Unit Subsidy		ABA Limit	Comments
Line Item						
Alfacalcidol						
Cap 0.25 mcg	234,037	\$61,599	\$0.2632		C H 5%	
Cap 1 mcg	54,271	\$47,748	\$0.8798		C H 5%	
Oral drops 2 mcg per ml	14,540	\$44,114	\$3.0340		C H 5%	
Calcium carbonate						
<u>Tab</u>	8,991,144	\$261,822	\$0.0291		C H 5%	Preference for tab 1.25 g - 1.5 g.
Colecalciferol						
<u>Cap/Tab 1.25 mg</u>	4,692,968	\$1,427,460	\$0.3042		C H 5%	Preference for a tablet.
Docusate Sodium						
<u>Tab 50 mg</u>	995,163	\$31,845	\$0.0320		C H 5%	
<u>Tab 120 mg</u>	1,623,423	\$80,846	\$0.0498		C H 5%	
Famotidine						
Inj 10 mg per ml, 2 ml					H 5%	
Inj 10 mg per ml, 4 ml	15,022	\$85,655	\$5.7020		C H 5%	Note this is currently listed as a Cost Brand Source (CBS).
Fibre supplement						
<u>Powder/granules</u>	104,149,000	\$4,165,960	\$0.0400		C H 5%	Units and subsidy shown as per the ispaghula (psyllium) husk 500 g currently listed and expressed as 'per g'. Preference for a product containing psyllium husk.
Glibenclamide						
Tab 5 mg	194,701	\$14,603	\$0.0750		C H 5%	
Gliclazide						
<u>Tab 80 mg</u>	17,052,845	\$685,524	\$0.0402		C H 5%	
Hyoscine N-butylbromide						
<u>Inj 20 mg. 1 ml</u>	180,940	\$69,119	\$0.3820	@	C H 5%	
Iodine supplement						
<u>Tab 150 mcg elemental</u>	13,909,587	\$925,822	\$0.0666		C H 5%	Units and subsidy shown are for the currently listed potassium iodate.
Macrogol 3350 with potassium chloride, sodium bicarbonate and sodium chloride						
<u>Powder for oral soln 13.125 g with potassium chloride 46.6 mg.sodium bicarbonate 178.5 mg and sodium chloride 350.7 mg</u>	13,649,213	\$3,867,231	\$0.2833		C H 5%	
Macrogol 3350 with sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid						
<u>Powder for oral soln</u>					H 5%	
Magnesium sulphate						
<u>Inj 2 mmol per ml, 5ml</u>	23,838	\$89,464	\$3.7530	@	C H 5%	
Mebeverine hydrochloride						
<u>Tab 135 mg</u>	2,970,190	\$280,505	\$0.0944		C H 5%	
Multivitamins						
Tab (BPC cap strength)	18,137,430	\$335,542	\$0.0185		C H 5%	
Nystatin						
<u>Oral liq 100,000 u per ml</u>	1,740,792	\$161,023	\$0.0925		C H 5%	
Omeprazole						
Inf 40 mg					H 5%	Currently listed in the hospital on the Pharmaceutical Schedule as Inj 40 mg. Aggregated tender bids cannot be made across inf, inj and caps.
Inj 40 mg	7,942	\$59,374	\$7.4760		C H 5%	Currently listed on the Pharmaceutical Schedule as Inj 40 mg ampoule with diluent. Aggregated tender bids cannot be made across inf, inj and caps.
<u>Cap 10 mg</u>	8,797,755	\$201,381	\$0.0229		C H 5%	Preference for a pack size of 30 or 90 capsules in a bottle pack. Aggregated tender bids cannot be made across inf, inj and caps.

Principal Supply Status

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Alimentary Tract and Metabolism

Chemical Name Line Item	Units	Cost	Unit Subsidy	ABA Limit	Comments
Omeprazole					
<u>Cap 20 mg</u>	120,039,820	\$2,693,694	\$0.0224	C H 5%	Preference for a pack size of 30 or 90 capsules in a bottle pack. Aggregated tender bids cannot be made across inf, inj and caps.
<u>Cap 40 mg</u>	35,514,336	\$1,254,721	\$0.0353	C H 5%	Preference for a pack size of 30 or 90 capsules in a bottle pack. Aggregated tender bids cannot be made across inf, inj and caps.
Pancreatic enzyme					
Cap 150 mg	2,790,918	\$974,868	\$0.3493	C H 5%	Pharmac would consider bids which contain the ranges of 9,000 -11,000BP u lipase, 8,000-10,000 BP u amylase and 150-600 BP u protease.
Cap 175 mg				C H 5%	Not currently listed on the Pharmaceutical Schedule. Pharmac would consider bids which contain the ranges of 20,000-25,000 BP u lipase, 22,500 BP u amylase and 1250 BP u protease.
Cap 300 mg	8,114,966	\$7,658,905	\$0.9438	C H 5%	Pharmac would consider bids which contain the range of 24,000-25,000 BP u lipase, 18,000 BP u amylase and 1,000-1,500 BP u protease.
Cap 420 mg				C H 5%	Not currently listed on the Pharmaceutical Schedule. Pharmac would consider bids which contain the range of 25,000-26,000 BP u lipase, 35,000 BP u amylase and 1,000-1,600 BP u protease.
Poloxamer					
<u>Oral drops 10%</u>	268,380	\$37,305	\$0.1390	C H 5%	
Pyridoxine hydrochloride					
<u>Tab 25 mg</u>	1,690,070	\$64,409	\$0.0381	C H 5%	
Triamcinolone acetonide					
<u>0.1% in Dental Paste USP</u>	148,375	\$162,916	\$1.0980	C H 5%	Aggregated tender bids cannot be made across dental paste, crm, inj and oint.
Ursodeoxycholic acid					
<u>Cap 250 mg - 300 mg</u>	1,429,727	\$485,392	\$0.3395	C H 5%	Units and subsidy shown are for the currently listed cap 200 mg.

Blood and Blood Forming Organs

Chemical Name Line Item	Units	Cost	Unit Subsidy	ABA Limit	Comments
Aspirin					
<u>Tab 100 mg</u>	87,001,576	\$1,111,880	\$0.0128	C H 5%	
Glucose [Dextrose]					
<u>Inj 50%, 10 ml - 20 ml</u>	12,219	\$84,922	\$6.9500	C H 5%	Inj 50%, 10 ml is currently listed on the Pharmaceutical Schedule. Units and subsidy are shown per 10 ml ampoule.
<u>Inj 50%, 90 ml - 100 ml</u>	386	\$6,755	\$17.5000	C H 5%	Inj 50%, 90 ml is currently listed on the Pharmaceutical Schedule. Units and subsidy are shown per 90 ml ampoule.
Prasugrel					
Tab 10 mg				C H 5%	Not currently listed on the Pharmaceutical Schedule. Special Authority restrictions may apply. Preference for a tablet containing a scoreline.
Tab 5 mg				C H 5%	Not currently listed on the Pharmaceutical Schedule. Special Authority restrictions may apply.
Water for injection					
Purified for inj, 250 ml bag				H 5%	

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Cardiovascular System

Chemical Name	Units	Cost	Unit Subsidy	ABA Limit	Comments
Line Item					
ACE Inhibitor					
Oral liquid	73,900	\$63,554	\$0.8600	C H 5%	Units and subsidy shown are for the currently listed captopril oral liq.
Ambrisentan					
Tab 5 mg	7,321	\$48,807	\$6.6667	C H 5%	
Tab 10 mg	22,072	\$147,147	\$6.6667	C H 5%	
Amloride hydrochloride with furosemide					
Tab 5 mg with furosemide 40 mg	110,718	\$34,124	\$0.3082	C H 5%	
Amlodipine					
Tab 2.5 mg	19,359,977	\$311,889	\$0.0161	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.
Tab 5 mg	35,089,318	\$471,600	\$0.0134	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.
Tab 10 mg	18,412,763	\$268,090	\$0.0146	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.
Bendroflumethiazide [Bendrofluazide]					
Tab 2.5 mg	15,641,629	\$1,611,088	\$0.1030	C H 5%	
Tab 5 mg	2,532,266	\$308,936	\$0.1220	C H 5%	
Bisoprolol fumarate					
Tab 2.5 mg	20,387,770	\$308,059	\$0.0151	C H 5%	Preference for a scored tablet, and for a pack size of 30 or 90 tablets in a bottle pack.
Tab 5 mg	10,089,837	\$214,106	\$0.0212	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.
Tab 10 mg	3,198,174	\$96,297	\$0.0301	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.
Clonidine					
TDDS 2.5 mg, 100 mcg per day	86,831	\$253,981	\$2.9250 @	C H 5%	
TDDS 5 mg, 200 mcg per day	31,644	\$101,261	\$3.2000 @	C H 5%	
TDDS 7.5 mg, 300 mcg per day	25,654	\$114,802	\$4.4750 @	C H 5%	
Colestyramine					
Powder for oral liq 4 g	659,971	\$811,764	\$1.2300	C H 5%	
Ephedrine					
Inj 3 mg per ml, 10 ml prefilled syringe				H 5%	
Inj 30 mg per ml, 1ml				H 5%	
Ezetimibe					
Tab 10 mg	12,408,222	\$727,990	\$0.0587	C H 5%	
Furosemide [Frusemide]					
Tab 20 mg				C H 5%	Not currently listed on the Pharmaceutical Schedule.
Indapamide					
Tab 2.5 mg	2,157,711	\$383,598	\$0.1778	C H 5%	
Isosorbide mononitrate					
Tab 20 mg	680,162	\$152,968	\$0.2249	C H 5%	
Tab long-acting 40 mg	769,986	\$251,531	\$0.3267	C H 5%	
Tab long-acting 60 mg	6,252,824	\$937,924	\$0.1500	C H 5%	
Ivabradine					
Tab 5 mg				H 5%	
Labetalol					
Tab 100 mg	1,130,502	\$163,923	\$0.1450	C H 5%	
Tab 200 mg	724,296	\$195,560	\$0.2700	C H 5%	
Losartan					
Tab 12.5 mg	5,895,998	\$140,384	\$0.0238	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Cardiovascular System

Chemical Name	Units	Cost	Unit Subsidy	ABA Limit	Comments
Line Item					
Losartan					
<u>Tab 25 mg</u>	13,689,621	\$373,179	\$0.0273	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.
<u>Tab 50 mg</u>	24,989,840	\$850,904	\$0.0341	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.
<u>Tab 100 mg</u>	13,690,476	\$744,762	\$0.0544	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.
Metaraminol Tartrate					
<u>Inj 10 mg per ml, 1 ml</u>			@	H 5%	
Metoprolol succinate					
<u>Tab long-acting Very Low Dose (20-25 mg)</u>	23,246,889	\$1,084,932	\$0.0467	C H 5%	Units and subsidy shown are for the currently listed tab 23.75 mg.
<u>Tab long-acting Low Dose (40-50 mg)</u>	32,686,631	\$1,325,770	\$0.0406	C H 5%	Units and subsidy shown are for the currently listed tab 47.5 mg.
<u>Tab long-acting Medium Dose (90-100 mg)</u>	19,815,103	\$1,153,635	\$0.0582	C H 5%	Units and subsidy shown are for the currently listed tab 95 mg.
<u>Tab long-acting High Dose (180-200 mg)</u>	3,572,018	\$387,350	\$0.1084	C H 5%	Units and subsidy shown are for the currently listed tab 190 mg.
Nifedipine					
Tab long-acting 10 mg	494,796	\$171,590	\$0.3468	C H 5%	
Tab long-acting 20 mg	801,348	\$141,999	\$0.1772	C H 5%	
Tab long-acting 30 mg	692,453	\$236,424	\$0.3414	C H 5%	
Tab long-acting 60 mg	128,852	\$68,047	\$0.5281	C H 5%	
Perindopril with amlodipine					
Tab 10 mg with amlodipine 10 mg				C H 5%	Not currently listed on the Pharmaceutical Schedule. Pharmac would consider funding perindopril with amlodipine if cost saving or cost neutral to current combined cost of funded ACE inhibitor and calcium channel blocker.
Tab 10 mg with amlodipine 5 mg				C H 5%	Not currently listed on the Pharmaceutical Schedule. Pharmac would consider funding perindopril with amlodipine if cost saving or cost neutral to current combined cost of funded ACE inhibitor and calcium channel blocker.
Tab 5 mg with amlodipine 10 mg				C H 5%	Not currently listed on the Pharmaceutical Schedule. Pharmac would consider funding perindopril with amlodipine if cost saving or cost neutral to current combined cost of funded ACE inhibitor and calcium channel blocker.
Tab 5 mg with amlodipine 5 mg				C H 5%	Not currently listed on the Pharmaceutical Schedule. Pharmac would consider funding perindopril with amlodipine if cost saving or cost neutral to current combined cost of funded ACE inhibitor and calcium channel blocker.
Pravastatin					
<u>Tab 20 mg</u>	3,357,836	\$240,421	\$0.0716	C H 5%	
<u>Tab 40 mg</u>	1,977,605	\$242,257	\$0.1225	C H 5%	
Prazosin Hydrochloride					
Tab 1 mg	52,758	\$2,918	\$0.0553	C H 5%	
Tab 2 mg	34,352	\$2,405	\$0.0700	C H 5%	
Tab 5 mg	10,298	\$1,205	\$0.1170	C H 5%	
Propranolol					
Oral liq 4 mg per ml	273,477			C H 0%	Note this is currently listed as a Cost Brand Source (CBS). Units are expressed as 'per ml'

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Cardiovascular System

Chemical Name	Units	Cost	Unit Subsidy	ABA Limit	Comments
Line Item					
Rosuvastatin (current access)					
Tab 10 mg	4,284,988	\$241,373	\$0.0563	C H 5%	Current restriction would apply. Pharmac would only award a tender for current or widened access.
Tab 20 mg	5,682,965	\$513,342	\$0.0903	C H 5%	Current restriction would apply. Pharmac would only award a tender for current or widened access.
Tab 40 mg	5,741,616	\$870,831	\$0.1517	C H 5%	Current restriction would apply. Pharmac would only award a tender for current or widened access.
Tab 5 mg	2,138,516	\$91,956	\$0.0430	C H 5%	Current restriction would apply. Pharmac would only award a tender for current or widened access.
Rosuvastatin (widened access)					
Tab 10 mg				C H 5%	Current restriction would not apply. Pharmac would only award a tender for current or widened access.
Tab 20 mg				C H 5%	Current restriction would not apply. Pharmac would only award a tender for current or widened access.
Tab 40 mg				C H 5%	Current restriction would not apply. Pharmac would only award a tender for current or widened access.
Tab 5 mg				C H 5%	Current restriction would not apply. Pharmac would only award a tender for current or widened access.
Simvastatin					
Tab 10 mg	2,270,930	\$42,398	\$0.0187	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.
Tab 20 mg	9,254,200	\$261,154	\$0.0282	C H 5%	Prefernce for a pack size of 30 or 90 tablets in a bottle pack.
Tab 40 mg	7,972,428	\$364,101	\$0.0457	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.
Tab 80 mg	558,746	\$54,696	\$0.0979	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.
Telmisartan					
Tab 40 mg				C H 5%	Not currently listed on the Pharmaceutical Schedule. Pharmac would consider funding telmisartan if cost saving or cost neutral to a current angiotensin II antagonist.
Tab 80 mg				C H 5%	Not currently listed on the Pharmaceutical Schedule. Pharmac would consider funding telmisartan if cost saving or cost neutral to a current angiotensin II antagonist.
Telmisartan with amlodipine					
Tab 40 mg with amlodipine 10 mg				C H 5%	Not currently listed on the Pharmaceutical Schedule. Pharmac would consider funding telmisartan with amlodipine if cost saving or cost neutral to current combined cost of funded angiotensin II antagonist and calcium channel blocker.
Tab 40 mg with amlodipine 5 mg				C H 5%	Not currently listed on the Pharmaceutical Schedule. Pharmac would consider funding telmisartan with amlodipine if cost saving or cost neutral to current combined cost of funded angiotensin II antagonist and calcium channel blocker.
Tab 80 mg with amlodipine 10 mg				C H 5%	Not currently listed on the Pharmaceutical Schedule. Pharmac would consider funding telmisartan with amlodipine if cost saving or cost neutral to current combined cost of funded angiotensin II antagonist and calcium channel blocker.

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Cardiovascular System

Chemical Name	Units	Cost	Unit Subsidy	ABA Limit	Comments
Line Item					
Telmisartan with amlodipine					
Tab 80 mg with amlodipine 5 mg				C H 5%	Not currently listed on the Pharmaceutical Schedule. Pharmac would consider funding telmisartan with amlodipine if cost saving or cost neutral to current combined cost of funded angiotensin II antagonist and calcium channel blocker.

Dermatologicals

Chemical Name	Units	Cost	Unit Subsidy	ABA Limit	Comments
Line Item					
Acitretin					
Cap 10 mg	583,616	\$254,848	\$0.4367	C H 5%	Preference for a blister pack.
Cap 25 mg	104,120	\$99,556	\$0.9562	C H 5%	Preference for a blister pack.
Adapalene (current access)					
Crm 0.1%				C H 5%	Same restriction as adapalene gel 0.1% would apply. Not currently listed in the community on the Pharmaceutical Schedule. Pharmac would only award a tender for current or widened access.
Gel 0.1%	1,007,370	\$768,623	\$0.7630#	C H 5%	Current restriction would apply. Pharmac would only award a tender for current or widened access.
Adapalene (widened access)					
Crm 0.1%				C H 5%	Restrictions would not apply. Not currently listed in the community on the Pharmaceutical Schedule. Pharmac would only award a tender for current or widened access.
Gel 0.1%				C H 5%	Current restriction would not apply. Pharmac would only award a tender for current or widened access.
Amorolfine					
Nail soln 5%	291,905	\$1,276,792	\$4.3740	C H 5%	
Benzyl benzoate (funded with restriction)					
10% - 25%				C H 5%	Restricted to scabies hyper-infestation or for second line treatment where topical therapy has failed. Not currently listed on the Schedule. Pharmac would only award a tender for benzyl benzoate funded with restriction or funded without restriction.
Benzyl benzoate (funded without restriction)					
10% - 25%				C H 5%	Not currently listed on the Pharmaceutical Schedule. Pharmac would only award a tender for benzyl benzoate funded with restriction or funded without restriction.
Betamethasone Dipropionate					
Crm 0.05% (pack size greater than 30 g)	639,530	\$460,462	\$0.7200	C H 5%	
Oint 0.05% (pack size greater than 30 g)	420,760	\$302,947	\$0.7200	C H 5%	
Ciclopirox olamine					
Nail lacquer 8%				C H 5%	Not current listed in the community on the Pharmaceutical Schedule. Special Authority restrictions may apply.
Dimethicone					
Crm 10%	4,091,240	\$40,201	\$0.0098	C H 5%	Preference for a pump bottle.
Econazole nitrate					
Foaming soln 1%, 10 ml sachets	42,828	\$141,190	\$3.2967 *	C H 5%	Awarding this Tender item would result in removal of the part charge.
Emulsifying ointment					
Oint BP (pack size of 200 g or less)				H 5%	Preference for an SLS-free product
Oint BP (pack size greater than 200 g)	42,092,892	\$263,502	\$0.0063	C H 5%	Preference for an SLS-free product
Principal Supply Status				#=rebate *=part charge @=ASP +=patent	

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Dermatologicals

Chemical Name Line Item	Units	Cost	Unit Subsidy	ABA Limit	Comments
Hydrocortisone with paraffin liquid and lanolin					
<u>Lotn 1% with paraffin liquid and lanolin (pack size 50 - 250 ml)</u>	13,488,782	\$692,244	\$0.0513	C H 5%	
Ketoconazole					
<u>Shampoo 2%</u>	9,091,600	\$371,846	\$0.0409	C H 5%	
Malathion (funded with restriction)					
0.5%				C H 5%	Restricted to scabies hyper-infestation or for second line treatment where topical therapy has failed. Not currently listed on the Schedule. Pharmac would only award a tender for malathion funded with restriction or funded without restriction.
Malathion (funded without restriction)					
0.5%				C H 5%	Not currently listed on the Pharmaceutical Schedule. Pharmac would only award a tender for malathion funded with restriction or funded without restriction.
Methylprednisolone aceponate					
<u>Crm 0.1%</u>	538,065	\$177,561	\$0.3300	C H 5%	
<u>Oint 0.1%</u>	299,685	\$98,896	\$0.3300	C H 5%	
Miconazole nitrate					
<u>Crm 2% (15 g - 20 g pack)</u>	3,524,745	\$211,485	\$0.0600	C H 5%	A 15 g pack is currently listed on the Pharmaceutical Schedule.
Paraffin					
<u>White soft (pack size 2000 g or more)</u>	1,979,122	\$15,041	\$0.0076	C 5%	Only funded in combination.
<u>White soft (pack size 500 g or less)</u>	128,146	\$1,350	\$0.0105	C H 5%	
Permethrin (combined market)					
Crm 5%				C H 5%	Not currently listed on the Pharmaceutical Schedule. Pharmac reserves the right to award a single tender for the whole permethrin market or two separate tenders for cream and lotion.
<u>Lotn 5%</u>	6,266,160	\$893,993	\$0.1427	C H 5%	Pharmac reserves the right to award a single tender for the whole permethrin market or two separate tenders for cream and lotion.
Permethrin (split market)					
Crm 5%				C H 5%	Not currently listed on the Pharmaceutical Schedule. Pharmac reserves the right to award a single tender for the entire permethrin market or two separate tenders for cream and lotion.
<u>Lotn 5%</u>	6,266,160	\$893,993	\$0.1427	C H 5%	Pharmac reserves the right to award a single tender for the entire permethrin market or two separate tenders for cream and lotion.
Pimecrolimus					
<u>Crm 1%</u>	183,285	\$403,227	\$2.2000	C H 5%	Restrictions may apply.
Pine tar with triethanolamine lauryl sulphate and fluorescein					
<u>Soln 2.3% with triethanolamine lauryl sulphate and fluorescein sodium</u>	23,272,107	\$251,804	\$0.0108	C H 5%	
Sulfadiazine silver					
1%	343,450	\$74,185	\$0.2160	C H 5%	Current restrictions apply. Pharmac would award a tender for any topical formulation.
Tacrolimus					
<u>Oint 0.1%</u>	304,560	\$335,016	\$1.1000	C H 5%	Restrictions may apply.
Triamcinolone acetonide					
<u>Crm 0.02%</u>	6,142,600	\$398,655	\$0.0649	C H 5%	Aggregated tender bids cannot be made across dental paste, crm, inj and oint.

Principal Supply Status

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Dermatologicals					
Chemical Name			Unit		
Line Item	Units	Cost	Subsidy	ABA Limit	Comments
Triamcinolone acetonide					

Genito-Urinary System						
Chemical Name						
Line Item	Units	Cost	Unit Subsidy		ABA Limit	Comments
Cyproterone acetate with ethinyloestradiol						
<u>Tab 2 mg with ethinyloestradiol 35 mcg and 7 inert tablets</u>	7,982,100	\$241,379	\$0.0302	C H	5%	
Finasteride						
<u>Tab 5 mg</u>	7,672,069	\$367,492	\$0.0479	C H	5%	Preference for a blister pack.
Intra-uterine device (Non-hormonal)						
IUD Long	2,185	\$72,105	\$33.0000	C H	5%	Preference for a product that carries an in-situ life of 10 years. Preference for a product with MDR certification. Special terms apply see Schedule 5.
IUD Medium	4,240	\$113,632	\$26.8000	C H	5%	Preference for a product that carries an in-situ life of 10 years. Preference for a product with MDR certification. Special terms apply see Schedule 5.
IUD Short	4,204	\$125,279	\$29.8000	C H	5%	Preference for a product that carries an in-situ life of 10 years. Preference for a product with MDR certification. Special terms apply see Schedule 5.
Nystatin						
<u>Vaginal crm 100,000 u per 5 g with applicator(s)</u>	166,725	\$12,671	\$0.0760	C H	5%	Units and subsidy expressed as 'per g'.
Oestriol						
<u>Crm 1 mg per g with applicator(s)</u>	5,784,870	\$2,680,304	\$0.4633	C H	5%	Applicator(s) should be multiple use and a measured dose.
<u>Pessaries 500 mcg</u>	602,361	\$303,186	\$0.5033	C H	5%	
Urinary alkaliniser						
<u>Effervescent</u>	2,135,481	\$266,935	\$0.1250	C H	5%	Units and subsidy shown are for the currently listed sodium citro-tartrate grans

Hormone Preparations - Systemic Excluding Contraceptive Hormones						
Chemical Name						
Line Item	Units	Cost	Unit Subsidy		ABA Limit	Comments
Cabergoline						
Tab 0.5 mg (2 pack)	100,678	\$225,769	\$2.2425	C H	5%	Current Special Authority restrictions would apply. Units and cost shown are for the whole tab 0.5 mg market.
Tab 0.5 mg (8 pack)	100,678	\$225,769	\$2.2425	C H	5%	Current Special Authority restrictions would apply. Units and cost shown are for the whole tab 0.5 mg market.
Desmopressin acetate						
<u>Nasal spray 10 mcg per dose</u>	794,754	\$462,944	\$0.5825	C H	5%	
Oestriol						
<u>Tab 1 mg - 2 mg</u>	172,547	\$44,288	\$0.2567	C H	5%	Units and subsidy shown are for the currently listed tab 2 mg. Preference for 2 mg tablets to be scored.
Propylthiouracil						
Tab 50 mg	281,864	\$98,652	\$0.3500	C H	5%	

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Hormone Preparations - Systemic Excluding Contraceptive Hormones

Chemical Name	Units	Cost	Unit Subsidy	ABA Limit	Comments
Line Item					
Triamcinolone acetonide					
<u>Inj 10 mg per ml, 1 ml</u>	5,767	\$24,706	\$4.2840	C H 10%	Preference for a preservative free product. Where a preservative free product is not awarded Pharmac reserves the right to list a preservative free product in addition to this product. Aggregated bids cannot be made across dental paste, crm, inj and oint.
<u>Inj 40 mg per ml, 1 ml</u>	80,097	\$843,101	\$10.5260	C H 5%	Preference for a preservative free product. Where a preservative free product is not awarded Pharmac reserves the right to list a preservative free product in addition to this product. Aggregated bids cannot be made across dental paste, crm, inj and oint.

Infections					
Chemical Name	Units	Cost	Unit Subsidy	ABA Limit	Comments
Line Item					
Amoxicillin					
<u>Grans for oral liq 125 mg per 5 ml</u>	3,821,769	\$84,843	\$0.0222 @	C H 5%	Preference for a product which includes a measuring device and has a shelf life of at least 10 days after reconstitution.
<u>Grans for oral liq 250 mg per 5 ml</u>	54,422,863	\$1,529,282	\$0.0281 @	C H 5%	Preference for a product which includes a measuring device and has a shelf life of at least 10 days after reconstitution.
Amoxicillin clavulanate					
<u>Tab 500 mg with potassium clavulanate 125 mg</u>	11,240,505	\$1,787,240	\$0.1590 @	C H 5%	
Benzylpenicillin sodium [Penicillin G]					
<u>Inj 600 mg</u>	7,335	\$12,103	\$1.6500 @	C H 5%	
Cefazolin sodium					
<u>Inj 500 mg</u>	276	\$187	\$0.6780	C H 5%	
<u>Inj 1 g</u>	17,881	\$12,839	\$0.7180	C H 5%	
<u>Inj 2 g</u>	1,094	\$1,551	\$1.4180	C H 5%	
Cefotaxime					
<u>Inj 500 mg</u>				H 5%	
<u>Inj 1 g</u>				H 5%	
Ceftazidime					
<u>Inj 1 g</u>				H 5%	
Cefuroxime sodium					
<u>Inj 250 mg</u>				H 5%	Not currently listed on the Pharmaceutical Schedule. Special Authority restrictions may apply.
<u>Inj 750 mg</u>				H 5%	
<u>Inj 1.5 g</u>				H 5%	
Chloramphenicol					
<u>Inj 1 g</u>				H 5%	Current restrictions may apply.
Ciprofloxacin					
<u>Tab 250 mg</u>	95,601	\$6,658	\$0.0696	C H 5%	Preference for a scored, dispersible tablet.
<u>Tab 500 mg</u>	658,181	\$72,867	\$0.1107	C H 5%	Preference for a scored, dispersible tablet.
<u>Tab 750 mg</u>	21,795	\$3,736	\$0.1714	C H 5%	Preference for a scored, dispersible tablet.
Clarithromycin					
<u>Inj 500 mg</u>				H 5%	
Colistin sulphomethate					
<u>Inj 1,000,000 - 4,500,000 iu</u>	420	\$9,100	\$21.6670	C H 5%	
Darunavir					
<u>Tab 400 mg</u>	90,476	\$226,190	\$2.5000	C H 5%	Preference for a dispersible tablet.
<u>Principal Supply Status</u>					
#=rebate *=part charge @=ASP +=patent					

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Infections							
Chemical Name							
Line Item	Units	Cost	Unit Subsidy		ABA Limit	Comments	
Darunavir							
Tab 600 mg	25,670	\$96,263	\$3.7500		C H 5%	Preference for a dispersible tablet.	
Entecavir							
Tab 0.5 mg	1,666,587	\$668,851	\$0.4013		C H 5%		
Ertapenem							
Inj 1 g					H 5%		
Flucloxacillin sodium							
Inj 250 mg	90	\$383	\$4.2600		C H 5%		
Inj 500 mg	608	\$2,774	\$4.5630		C H 5%		
Inj 1 g	4,569	\$5,483	\$1.2000		C H 5%		
Fluconazole							
Cap 50 mg	265,383	\$38,860	\$0.1464		C H 5%		
Cap 150 mg	160,992	\$72,446	\$0.4500		C H 5%		
Cap 200 mg	83,518	\$26,547	\$0.3179		C H 5%		
Lamivudine							
Tab 100 mg	55,929	\$24,089	\$0.4307		C H 5%		
Tab 150 mg	47,749	\$77,990	\$1.6333		C H 5%		
Meropenem							
Inj 500 mg					H 5%		
Inj 1 g				@	H 5%		
Metronidazole							
Tab 200 mg	301,749	\$31,213	\$0.1034		C H 5%	Preference for a scored, dispersible tablet.	
Tab 400 mg	2,185,844	\$446,546	\$0.2043		C H 5%		
Inj 5 mg per ml, 100 ml				@	H 5%	Preference for a bag presentation with space to add another antibiotic.	
Minocycline hydrochloride							
Inj 100 - 200 mg					H 5%	Not currently listed on the Pharmaceutical Schedule. Special Authority restrictions may apply.	
Moxifloxacin							
Inj 400 mg					H 5%		
Tab 400 mg	20,582	\$172,885	\$8.4000		C H 5%		
Nitrofurantoin							
Cap modified-release 100 mg	2,119,477	\$1,721,015	\$0.8120		C H 5%		
Pentamidine							
Inj 300 mg					H 5%		
Rifampicin							
Cap 150 mg	70,091	\$41,031	\$0.5854	@	C H 5%	Aggregated tender bids cannot be made across caps, inj and oral liq.	
Cap 300 mg	226,819	\$276,855	\$1.2206	@	C H 5%	Aggregated tender bids cannot be made across caps, inj and oral liq.	
Inj 600 mg					H 5%	Aggregated tender bids cannot be made across caps, inj and oral liq.	
Oral liq 100 mg per 5 ml	73,691	\$15,475	\$0.2100	@	C H 5%	Aggregated tender bids cannot be made across caps, inj and oral liq.	
Rifampicin with isoniazid and ethambutol and pyrazinamide							
150 mg with isoniazid 75 mg and ethambutol 275 mg and pyrazinamide 400 mg					C H 5%	Not currently listed on the Pharmaceutical Schedule. Restrictions may apply. Pharmac would award a tender for any oral formulation of this combination.	
Rifampicin with isoniazid and pyrazinamide							
150 mg with isoniazid 75 mg and pyrazinamide 400 mg					C H 5%	Not currently listed on the Pharmaceutical Schedule. Restrictions may apply. Pharmac would award a tender for any oral formulation of this combination.	

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Infections							
Chemical Name	Units	Cost	Unit Subsidy		ABA Limit	Comments	
Line Item							
Roxithromycin							
Tab 150 mg	1,388,218	\$366,212	\$0.2638	@	C H	5%	
Tab 300 mg	746,508	\$373,254	\$0.5000	@	C H	5%	
Terbinafine							
Tab 250 mg	2,468,564	\$263,618	\$0.1068		C H	5%	
Tobramycin							
Solution for inhalation 60 mg per ml, 5 ml	4,788	\$33,772	\$7.0536		C H	5%	Preference for a product that is sodium bisulfite free and/or preservative free and/or suitable for use via nebuliser.
Vancomycin hydrochloride							
Inj 500 mg	8,218	\$27,777	\$3.3800	@	C H	5%	
Vancomycin hydrochloride (current access)							
Cap 125 mg					C H	5%	Not currently listed on the Pharmaceutical Schedule. Special Authority restrictions may apply. Pharmac would only award a tender for current or widened access.
Cap 250 mg					C H	5%	Not currently listed on the Pharmaceutical Schedule. Special Authority restrictions may apply. Pharmac would only award a tender for current or widened access.
Vancomycin hydrochloride (widened access)							
Cap 125 mg					C H	5%	For treatment of Clostridium difficile in line with 2025 Australasian Society of Infectious Diseases guidelines. Not currently listed on the Pharmaceutical Schedule. Restrictions may apply. Pharmac would only award a tender for current or widened access.
Cap 250 mg					C H	5%	For treatment of Clostridium difficile in line with 2025 Australasian Society of Infectious Diseases guidelines. Not currently listed on the Pharmaceutical Schedule. Restrictions may apply. Pharmac would only award a tender for current or widened access.
Voriconazole							
Powder for oral suspension 40 mg per ml	8,120	\$176,694	\$21.7603		C H	5%	
Musculoskeletal System							
Chemical Name	Units	Cost	Unit Subsidy		ABA Limit	Comments	
Line Item							
Allopurinol							
Tab 100 mg	32,681,609	\$587,942	\$0.0180		C H	5%	Preference for a scored tablet.
Tab 300 mg	24,038,383	\$1,081,727	\$0.0450		C H	5%	Preference for a scored tablet.
Atracurium besylate							
Inj 10 mg per ml, 2.5 ml				@	H	5%	
Febuxostat							
Tab 80 mg	806,366	\$136,219	\$0.1689		C H	5%	Current restrictions may apply.
Tab 120 mg	192,534	\$81,001	\$0.4207		C H	5%	Current restrictions may apply.
Ibuprofen							
Tab 200 mg - blister pack (pack size greater than or equal to 100 and less than or equal to 1,000)	56,733,456	\$1,214,096	\$0.0214	@	C H	5%	
Tab 200 mg - blister pack (pack size less than or equal to 20)				@	H	5%	Not currently listed on the Pharmaceutical Schedule.
Suxamethonium chloride							
Inj 50 mg per ml, 2 ml				@	H	5%	

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Nervous System						
Chemical Name	Units	Cost	Unit Subsidy	ABA Limit	Comments	
Line Item						
Alfentanil						
Inj 0.5 mg per ml, 2 ml ampoule			@	H	5%	
Amitriptyline						
Tab 10 mg	27,073,774	\$809,506	\$0.0299	C H	5%	Preference for a scored and/or dispersible tablet.
Tab 25 mg	7,973,464	\$158,672	\$0.0199	C H	5%	
Tab 50 mg	3,337,898	\$104,810	\$0.0314	C H	5%	
Aripiprazole						
Tab 5 mg	1,210,474	\$423,666	\$0.3500	C H	5%	
Tab 10 mg	894,076	\$312,927	\$0.3500	C H	5%	
Tab 15 mg	325,364	\$113,877	\$0.3500	C H	5%	
Tab 20 mg	214,122	\$74,943	\$0.3500	C H	5%	
Tab 30 mg	98,915	\$34,620	\$0.3500	C H	5%	
Aspirin						
Tab dispersible or soluble 300 mg	622,871	\$35,192	\$0.0565	C H	5%	
Atomoxetine						
Cap 10 mg	365,900	\$562,180	\$1.5364	C H	5%	
Cap 18 mg	128,417	\$208,999	\$1.6275	C H	5%	
Cap 25 mg	327,944	\$518,853	\$1.5821	C H	5%	
Cap 40 mg	489,565	\$807,958	\$1.6504	C H	5%	
Cap 60 mg	115,832	\$212,262	\$1.8325	C H	5%	
Cap 80 mg	92,594	\$215,612	\$2.3286	C H	5%	
Cap 100 mg	47,699	\$111,940	\$2.3468	C H	5%	
Betahistine dihydrochloride						
Tab 16 mg	5,130,849	\$189,841	\$0.0370	C H	5%	
Bupivacaine hydrochloride						
Inj 2.5 mg per ml, 20 ml ampoule sterile pack				H	5%	Product needs to be sterile.
Inj 5 mg per ml, 4 ml				H	5%	
Dexmedetomidine hydrochloride						
Inj 100 mcg per ml, 2 ml vial			@	H	5%	
Diazepam						
Tab 2 mg	2,825,363	\$536,819	\$0.1900	C H	5%	Preference for a scored tablet.
Tab 5 mg	3,984,227	\$916,372	\$0.2300	C H	5%	
Disulfiram						
Tab 200 mg	429,666	\$1,015,729	\$2.3640	C H	5%	
Donepezil hydrochloride						
Tab 5 mg	1,826,587	\$80,461	\$0.0441	C H	5%	
Tab 10 mg	1,467,717	\$96,106	\$0.0655	C H	5%	
Duloxetine						
Cap 30 mg				C H	5%	Not currently listed on the Pharmaceutical Schedule. Special Authority restrictions may apply.
Cap 60 mg				C H	5%	Not currently listed on the Pharmaceutical Schedule. Special Authority restrictions may apply.
Escitalopram						
Tab 10 mg	18,102,687	\$510,677	\$0.0282	C H	5%	Preference for a scored tablet.
Tab 20 mg	6,586,917	\$350,490	\$0.0532	C H	5%	
Fentanyl						
Inj 10 mcg per ml, 100 ml premixed bag			@	H	5%	
Granisetron						
Inj 1 mg per ml				H	5%	

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Nervous System						
Chemical Name	Units	Cost	Unit Subsidy	ABA Limit	Comments	
Line Item						
Hyoscine hydrobromide						
Patch 1 mg per 72 hours	51,097	\$452,208	\$8.8500	C H	5%	
Lithium carbonate						
Immediate-release tab/cap	2,847,436	\$1,018,813	\$0.3578	C H	5%	Units and subsidy shown are for the currently listed cap 250 mg.
Metoclopramide hydrochloride						
Tab 10 mg	6,364,406	\$99,921	\$0.0157	C H	5%	
Morphine						
Oral liq 1 mg per ml	8,160,815	\$775,277	\$0.0950	C H	5%	Preference for a product with child-resistant packaging. Preference for an excipient free product. Aggregated tender bids cannot be made across inj and oral liq.
Oral liq 10 mg per ml	43,045	\$8,663	\$0.2013	C H	5%	Preference for a product with child-resistant packaging. Preference for an excipient free product. Aggregated tender bids cannot be made across inj and oral liq.
Oral liq 2 mg per ml	258,501	\$30,438	\$0.1178	C H	5%	Preference for a product with child-resistant packaging. Preference for an excipient free product. Aggregated tender bids cannot be made across inj and oral liq.
Oral liq 5 mg per ml	279,022	\$39,342	\$0.1410	C H	5%	Preference for a product with child-resistant packaging. Preference for an excipient free product. Aggregated tender bids cannot be made across inj and oral liq.
Inj 1 mg per ml, 10 ml syringe				H	5%	Aggregated tender bids cannot be made across inj and oral liq.
Inj 1 mg per ml, 50 ml syringe				H	5%	Aggregated tender bids cannot be made across inj and oral liq.
Inj 1 mg per ml, 100 ml bag				H	5%	Aggregated tender bids cannot be made across inj and oral liq.
Naltrexone hydrochloride						
Tab 50 mg	334,673	\$929,611	\$2.7777	C H	5%	
Nortriptyline hydrochloride						
Tab 10 mg	17,865,779	\$439,498	\$0.0246	C H	5%	
Tab 25 mg	10,052,149	\$351,222	\$0.0349	C H	5%	
Olanzapine						
Orodispersible tab 5 mg	541,016	\$46,760	\$0.0864	C H	5%	Aggregated tender bids cannot be made across orodispersible tabs and regular tabs.
Orodispersible tab 10 mg	707,263	\$72,997	\$0.1032	C H	5%	Aggregated tender bids cannot be made across orodispersible tabs and regular tabs.
Tab 2.5 mg	2,405,742	\$112,276	\$0.0467	C H	5%	Preference for a pack size of 30 or 90 tablets in a bottle pack. Aggregated tender bids cannot be made across orodispersible tabs and regular tabs.
Tab 5 mg	3,057,714	\$196,703	\$0.0643	C H	5%	Preference for a pack size of 30 or 90 tablets in a bottle pack. Aggregated tender bids cannot be made across orodispersible tabs and regular tabs.
Tab 10 mg	3,336,239	\$214,620	\$0.0643	C H	5%	Preference for a pack size of 30 or 90 tablets in a bottle pack. Aggregated tender bids cannot be made across orodispersible tabs and regular tabs.
Ondansetron						
Tab disp 4 mg	4,179,768	\$234,067	\$0.0560	C H	5%	
Tab disp 8 mg	1,467,673	\$132,091	\$0.0900	C H	5%	

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Nervous System							
Chemical Name			Unit				
Line Item	Units	Cost	Subsidy		ABA Limit	Comments	
Oxycodone hydrochloride							
Oral liq 1 mg per ml	576,572	\$85,517	\$0.1483		C H 5%	Preference for a pack size of 250 ml or less. Preference for a shelf life of at least 30 days after opening.	
Paracetamol							
Tab 500 mg - blister pack (pack size greater than or equal to 100 and less than or equal to 1,000)	403,413,550	\$7,967,418	\$0.0198	@	C H 5%		
Tab 500 mg - bottle pack (pack size greater than or equal to 1,000)	57,151,142	\$1,024,148	\$0.0179	@	C H 5%		
Suppos 125 mg	171,851	\$73,724	\$0.4290		C H 5%		
Suppos 250 mg	111,460	\$60,077	\$0.5390		C H 5%		
Suppos 500 mg	123,201	\$40,780	\$0.3310		C H 5%		
Prochlorperazine							
Tab 5 mg	3,941,959	\$394,196	\$0.1000		C H 5%		
Quetiapine							
Tab 25 mg	32,164,942	\$843,365	\$0.0262		C H 5%	Preference for a scored tablet. Preference for a pack size of 30 or 90 tablets in a blister pack.	
Tab 100 mg	4,338,131	\$308,484	\$0.0711		C H 5%	Preference for a pack size of 30 or 90 tablets in a blister pack.	
Tab 200 mg	1,135,901	\$138,455	\$0.1219		C H 5%	Preference for a pack size of 30 or 90 tablets in a blister pack.	
Tab 300 mg	492,015	\$86,541	\$0.1759		C H 5%	Preference for a pack size of 30 or 90 tablets in a blister pack.	
Remifentanil hydrochloride							
Inj 1 mg				@	H 5%		
Inj 2 mg				@	H 5%		
Risperidone							
Oral liq 1 mg per ml	519,024	\$178,025	\$0.3430		C H 5%		
Tab 0.5 mg	4,170,789	\$150,857	\$0.0362		C H 5%	Preference for a pack size of 60 tablets in a blister pack.	
Tab 1 mg	2,184,218	\$88,832	\$0.0407		C H 5%	Preference for a pack size of 60 tablets in a blister pack.	
Tab 2 mg	1,037,473	\$47,029	\$0.0453		C H 5%	Preference for a pack size of 60 tablets in a blister pack.	
Tab 3 mg	425,578	\$31,918	\$0.0750		C H 5%	Preference for a pack size of 60 tablets in a blister pack.	
Tab 4 mg	206,452	\$21,506	\$0.1042		C H 5%	Preference for a pack size of 60 tablets in a blister pack.	
Rizatriptan							
Tab orodispersible 10 mg	2,862,426	\$461,795	\$0.1613		C H 5%		
Ropivacaine hydrochloride							
Inj 2 mg per ml, 10 ml ampoule					H 5%		
Inj 2 mg per ml, 20 ml					H 5%		
Inj 2 mg per ml, 100 ml					H 5%		
Inj 2 mg per ml, 200 ml					H 5%		
Inj 7.5 mg per ml, 10 ml					H 5%		
Inj 7.5 mg per ml, 20 ml					H 5%		
Inj 10 mg per ml, 10 ml					H 5%		
Inj 10 mg per ml, 20 ml					H 5%		
Temazepam							
Tab 10 mg	2,990,025	\$167,441	\$0.0560		C H 5%	Preference for a scored tablet.	
Tramadol hydrochloride							
Cap 50 mg	28,470,542	\$948,069	\$0.0333		C H 5%	Please note that tramadol is classified as a controlled drug. Aggregated tender bids cannot be made across caps, inj and tabs.	

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Nervous System						
Chemical Name	Units	Cost	Unit Subsidy	ABA Limit Comments		
Line Item						
Tramadol hydrochloride						
<u>Inj 50 mg per ml, 1 ml ampoule</u>				H	5%	Please note that tramadol is classified as a controlled drug. Aggregated tender bids cannot be made across caps, inj and tabs.
<u>Inj 50 mg per ml, 2 ml ampoule</u>				H	5%	Please note that tramadol is classified as a controlled drug. Aggregated tender bids cannot be made across caps, inj and tabs.
<u>Tab sustained-release 100 mg</u>	4,555,330	\$444,145	\$0.0975	C H	5%	Please note that tramadol is classified as a controlled drug. Aggregated tender bids cannot be made across caps, inj and tabs.
<u>Tab sustained-release 150 mg</u>	375,910	\$55,447	\$0.1475	C H	5%	Please note that tramadol is classified as a controlled drug. Aggregated tender bids cannot be made across caps, inj and tabs.
<u>Tab sustained-release 200 mg</u>	253,890	\$48,239	\$0.1900	C H	5%	Please note that tramadol is classified as a controlled drug. Aggregated tender bids cannot be made across caps, inj and tabs.

Oncology Agents and Immunosuppressants						
Chemical Name	Units	Cost	Unit Subsidy	ABA Limit Comments		
Line Item						
Anastrozole						
<u>Tab 1 mg</u>	570,010	\$83,410	\$0.1463	C H	5%	
Bicalutamide						
<u>Tab 50 mg</u>	728,880	\$108,814	\$0.1493	C H	5%	
Calcium folinate						
Inj 350 mg				PCT	H	5%
Inj 50 mg		\$370,938	\$22.4400	PCT	C H	5% Please note this line item is currently listed on the Pharmaceutical Schedule as inj 10 mg per ml, 5 ml vial.
Inj 100 mg				PCT	H	5%
Inj 300 mg				PCT	H	5%
Inj 1 g				PCT	H	5%
Docetaxel						
<u>Inj 80 mg</u>				PCT	H	5% Preference for products where stability data >48 hours post-compounding.
Exemestane						
<u>Tab 25 mg</u>	582,154	\$191,337	\$0.3287	C H	5%	
Fludarabine phosphate						
Tab 10 mg	1,779	\$36,647	\$20.6000	PCT	C H	5% Preference for blister packaging.
Gemcitabine hydrochloride						
Inj 1 g				PCT	H	5% Not currently listed in the hospital on the Pharmaceutical Schedule. Special Authority restrictions may apply.
Hydroxyurea						
<u>Cap 500 mg</u>	1,509,348	\$312,737	\$0.2072	PCT	C H	5% Preference for a blister pack.
Imatinib mesilate						
<u>Cap 100 mg</u>	182,740	\$136,841	\$0.7488	C H	5%	
<u>Cap 400 mg</u>	144,158	\$335,215	\$2.3253	C H	5%	
Melfalan						
<u>Inj 50 mg vial</u>				PCT	H	5%
Methotrexate						
<u>Inj 100 mg per ml, 50 ml</u>				PCT	H	5% Preference for products where stability data >48 hours post-compounding.
Inj 100 mg per ml, 10 ml vial			\$25.0000	PCT	C H	5%
Octreotide						
Inj 50 mcg per ml, 1 ml	1,414	\$7,800	\$5.5160	C H	5%	
Inj 100 mcg per ml, 1 ml	5,014	\$48,636	\$9.7000	C H	5%	

Principal Supply Status

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Oncology Agents and Immunosuppressants

Chemical Name	Units	Cost	Unit Subsidy	ABA Limit	Comments
Line Item					
Octreotide					
Inj 500 mcg per ml, 1 ml	1,901	\$43,001	\$22.6200	C H 5%	
Paclitaxel					
Inj 100 mg				PCT H 5%	Preference for products where stability data >48 hours post-compounding.
Inj 300 mg				PCT H 5%	Preference for products where stability data >48 hours post-compounding.
Tamoxifen citrate					
Tab 10 mg	58,702	\$14,676	\$0.2500	C H 5%	
Tab 20 mg	1,633,289	\$144,824	\$0.0887	C H 5%	
Thiotepa					
Inj 15 mg				PCT H 5%	
Inj 100 mg				PCT H 5%	

Respiratory System and Allergies

Chemical Name	Units	Cost	Unit Subsidy	ABA Limit	Comments
Line Item					
Cetirizine hydrochloride					
Tab 10 mg	65,284,775	\$1,116,370	\$0.0171	C H 5%	Preference for a pack size of 90 tablets.

Sensory Organs

Chemical Name	Units	Cost	Unit Subsidy	ABA Limit	Comments
Line Item					
Atropine sulphate					
Eye drops 1%	135,765	\$165,362	\$1.2180	C H 5%	
Cyclopentolate hydrochloride					
Eye drops 1%	31,710	\$53,188	\$1.6773	C H 5%	
Latanoprost with timolol					
Eye drops 0.005% with timolol 0.5%	169,555	\$335,719	\$1.9800	C H 5%	
Timolol maleate					
Eye drops 0.25%	176,195	\$85,278	\$0.4840	C H 5%	For products containing BAK, Pharmac reserves the right to list a BAK or preservative free product for a restricted market. Please note that this line item is for non gel-forming drops.
Eye drops 0.5%	200,560	\$100,280	\$0.5000	C H 5%	For products containing BAK, Pharmac reserves the right to list a BAK or preservative free product for a restricted market. Please note that this line item is for non gel-forming drops.
Tropicamide					
Eye drops 0.5%	780	\$1,067	\$1.3680	C H 5%	Preference for a preservative free product. Where a preservative free product is not awarded Pharmac reserves the right to list a preservative free product in addition to this product. Units and unit subsidy expressed as "per ml".
Eye drops 1%	8,535	\$14,123	\$1.6547	C H 5%	Preference for a preservative free product. Where a preservative free product is not awarded Pharmac reserves the right to list a preservative free product in addition to this product. Unit and unit subsidy expressed as "per ml".